Technology ❯ Biotechnology ❯ mRNA Technology ❯ Lipid Nanoparticles
The deal gives Lilly a preclinical Tethosome non‑viral DNA delivery platform, a lipid‑nanoparticle approach designed to target potency, tolerability and re‑dosing limits in DNA therapies.
